Welcome to our dedicated page for Vanda Pharmaceuticals SEC filings (Ticker: VNDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Vanda Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Vanda Pharmaceuticals's regulatory disclosures and financial reporting.
Vanda Pharmaceuticals Inc. director Duncan Charles Cliff filed an initial statement of beneficial ownership on Form 3. This filing identifies him as a director of Vanda and provides a baseline disclosure of his equity position and reporting status, without showing any reportable transactions in the provided data.
Vanda Pharmaceuticals is asking stockholders to vote at its virtual 2026 annual meeting on June 4, 2026. Proposals include electing three Class II directors through 2029, ratifying PricewaterhouseCoopers as auditor, an advisory vote on executive pay and increasing shares under the 2016 Equity Incentive Plan.
The record date is April 17, 2026, with 60,135,062 common shares outstanding. The proxy highlights 2025 total revenue of $216.1 million, including Fanapt, HETLIOZ and PONVORY sales, year-end cash and securities of $263.8 million and a net loss of $220.5 million after a large non-cash tax valuation allowance. It also outlines multiple late-stage clinical programs, an FDA approval for tradipitant in motion sickness and a BLA filing for imsidolimab in generalized pustular psoriasis.
Vanda Pharmaceuticals Inc. expanded its Board of Directors from six to seven members and appointed Charles C. Duncan, Ph.D., as a Class II director, with his initial term running until the company’s 2026 annual stockholders’ meeting. Under Vanda’s outside director compensation program, Dr. Duncan received an initial restricted stock unit award with a grant date value of $390,000 as of April 22, 2026, vesting in four equal annual installments while he serves on the board, and he will receive a $50,000 annual cash fee paid quarterly. Beginning with the 2026 annual meeting, he will be eligible for additional annual restricted stock unit awards with a grant date value of $260,000, vesting one year from grant, with all such awards becoming fully vested upon a change of control. Vanda states that Dr. Duncan is an independent director and has entered into its standard Delaware law indemnification agreement for directors.
Vanda Pharmaceuticals Inc. executive Christos Vasilios Mihael Polymeropoulos, Senior VP and Medical Director, filed an initial ownership report showing his equity positions in the company. He holds a stock option to buy 61,200 shares of common stock at an exercise price of $7.05 per share, expiring on February 15, 2033. The filing also lists multiple common stock and restricted stock unit (RSU) awards, with time-based vesting schedules running from March 1, 2027 through March 1, 2029, contingent on his continued employment and delivery of vested shares on the first permissible trading day after each vest date.
Vanda Pharmaceuticals VP and Chief People Officer Howell Scott Laverne filed an initial ownership report showing a mix of stock options, restricted stock units and common shares. His derivative holdings include options covering 77,500 shares at $7.05 per share expiring on February 15, 2033, along with additional grants at higher exercise prices and earlier expiration dates. He also reports multiple direct common stock positions, including one line of 100,000 shares, plus 9,620 shares of common stock held indirectly through a foundation controlled by him and his family members.
Vanda Pharmaceuticals Inc. reported that Timothy Williams has resigned as Senior Vice President, General Counsel and Secretary. He notified the company on March 29, 2026, and his resignation will be effective April 10, 2026, as he plans to pursue other endeavors.
Vanda Pharmaceuticals Inc: The Vanguard Group filed Amendment No. 7 to its Schedule 13G/A reporting that it beneficially owns 0 shares (0%) of Vanda Pharmaceuticals Common Stock following an internal realignment of Vanguard subsidiaries.
The amendment explains certain Vanguard subsidiaries will report separately in reliance on SEC Release No. 34-39538 and states the subsidiaries pursue the same investment strategies previously pursued by The Vanguard Group, Inc. The form is signed by Ashley Grim on 03/27/2026.
Vanda Pharmaceuticals Inc. reported that its President, Chief Executive Officer and Chairman, Dr. Mihael Polymeropoulos, appeared on Fox Business’ Mornings with Maria to discuss pricing and commercial plans for a drug recently approved by the U.S. Food and Drug Administration to prevent vomiting caused by motion.
During the interview, he stated that Vanda is developing a direct-to-consumer channel to provide access to this drug and indicated that the channel is expected to be available in the next couple of months. The company furnished a link to the full televised interview for reference.
Vanda Pharmaceuticals Inc. executive Timothy Williams, its SVP & General Counsel, reported selling 42,434 shares of common stock on March 2, 2026. The shares were sold at a weighted average price of $8.2659 per share solely to satisfy tax obligations arising from the settlement of vested RSUs under the company’s RSU agreements. The transactions occurred in multiple trades at prices ranging from $8.085 to $8.81 per share. After these tax-related sales, Williams directly holds 377,450 shares of Vanda common stock.